JP2008536851A5 - 女性でテストステロンおよび関連ステロイドの濃度を増加させる医薬組成物および医薬キット - Google Patents
女性でテストステロンおよび関連ステロイドの濃度を増加させる医薬組成物および医薬キット Download PDFInfo
- Publication number
- JP2008536851A5 JP2008536851A5 JP2008506606A JP2008506606A JP2008536851A5 JP 2008536851 A5 JP2008536851 A5 JP 2008536851A5 JP 2008506606 A JP2008506606 A JP 2008506606A JP 2008506606 A JP2008506606 A JP 2008506606A JP 2008536851 A5 JP2008536851 A5 JP 2008536851A5
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- aqueous alcohol
- alcohol gel
- therapeutic agent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims 12
- 229960003604 Testosterone Drugs 0.000 title claims 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 150000003431 steroids Chemical class 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 5
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 239000003349 gelling agent Substances 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrugs Drugs 0.000 claims 2
- 239000000186 progesterone Substances 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 229960005309 Estradiol Drugs 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 230000037165 Serum Concentration Effects 0.000 claims 1
- 102000034956 Sex Hormone-Binding Globulin Human genes 0.000 claims 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960001566 methyltestosterone Drugs 0.000 claims 1
- ZQKOGDIJTMNWCT-UFQCMFJCSA-N methyltestosterone group Chemical group CC1[C@@H]2[C@]([C@H](C1)O)(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C ZQKOGDIJTMNWCT-UFQCMFJCSA-N 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 230000035936 sexual power Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
Claims (7)
- それを必要とする哺乳類の雌におけるテストステロン欠乏障害の治療、予防、またはその発病リスクの軽減のための経皮投与水性アルコールゲル医薬組成物であって、
a.0.1%から10%(w/w)のテストステロン、またはその塩、エステル、アミド、鏡像異性体、異性体、互変異性体、プロドラッグもしくは誘導体、
b.約30%〜約98%(w/w)のエタノールまたはイソプロパノールからなる群から選択されるアルコール、
c.0.1%から5%(w/w)の浸透促進剤、
d.0.1%から5%(w/w)のゲル化剤、および
e.バランス純水、
を含み、前記組成物が、投与後24時間以内にテストステロン血清濃度を少なくとも3pgテストステロン/ml血清に上昇させる速度および期間で皮膚にテストステロンを放出することができる。 - 前記組成物が性ホルモン結合グロブリンの合成を抑制する作用物質、プロゲステロン、プロゲスチンまたはエストロゲン様ホルモンを含む治療剤を0.01%から69%さらに含む、請求項1の水性アルコールゲル。
- 前記治療剤がプロゲステロンである請求項1または2の水性アルコールゲル。
- 前記治療剤がエストロゲンである請求項1または2の水性アルコールゲル。
- 前記治療剤がメチルテストステロンである請求項1または2の水性アルコールゲル。
- 前記治療剤がエストラジオールである請求項1または2の水性アルコールゲル。
- それを必要とする女性対象の性的能力を改善するための医薬キットあって、
(a)経皮投与のための水性アルコールゲル医薬組成物であって、
i.0.1%から10%(w/w)のテストステロン、またはその塩、エステル、アミド、鏡像異性体、異性体、互変異性体、プロドラッグもしくは誘導体、
ii.30%〜98%(w/w)のエタノールまたはイソプロパノールからなる群から選択されるアルコール、
iii.0.1%〜5%(w/w)の浸透促進剤、
iv.0.1%〜5%(w/w)のゲル化剤、および
v.バランス水
を含む水性アルコールゲル医薬組成物と、
(b)性的能力を改善するための作用物質と、
を含む。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67075305P | 2005-04-13 | 2005-04-13 | |
PCT/US2006/013550 WO2006113242A2 (en) | 2005-04-13 | 2006-04-11 | Method of increasing testosterone and related steroid concentrations in women |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008536851A JP2008536851A (ja) | 2008-09-11 |
JP2008536851A5 true JP2008536851A5 (ja) | 2009-05-28 |
Family
ID=37115670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008506606A Pending JP2008536851A (ja) | 2005-04-13 | 2006-04-11 | 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070154533A1 (ja) |
EP (1) | EP1868590A4 (ja) |
JP (1) | JP2008536851A (ja) |
KR (1) | KR20080016552A (ja) |
CA (1) | CA2604431A1 (ja) |
NO (1) | NO20075821L (ja) |
WO (1) | WO2006113242A2 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
JP2007537247A (ja) | 2004-05-11 | 2007-12-20 | エモーショナル ブレイン ビー.ブイ. | 女性性的機能不全の治療における薬学的製剤およびその使用方法 |
TR201815853T4 (tr) | 2005-10-12 | 2018-11-21 | Besins Healthcare Sarl | Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli. |
EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
EP2011496A1 (en) * | 2007-07-03 | 2009-01-07 | Indena S.P.A. | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
CA2704117C (en) * | 2007-11-02 | 2015-11-17 | Acrux Dds Pty Ltd | Transdermal delivery system |
US20090285893A1 (en) * | 2008-05-19 | 2009-11-19 | The Procter & Gamble Company | Treatment of heart failure in women |
CA2822435C (en) | 2009-12-31 | 2018-09-11 | Differential Drug Development Associates, Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
US20110202362A1 (en) * | 2010-02-17 | 2011-08-18 | Western Holdings, Llc | Weight loss method and system for performing and monitoring the same |
AU2011329782A1 (en) | 2010-11-18 | 2013-06-20 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
JP6562630B2 (ja) * | 2011-05-13 | 2019-08-21 | エーセラス ファーマシューティカルズ コーポレーション | 経鼻投与用の低投薬濃度テストステロンゲル製剤および無オルガズム症または性的欲求低下障害を治療するためのその使用 |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
CN105188670B (zh) | 2013-03-15 | 2018-11-02 | 马留斯医药有限责任公司 | 乳液制剂 |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
WO2016033556A1 (en) * | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CN109982691A (zh) | 2016-10-06 | 2019-07-05 | 韩国迪外天然健康株式会社 | 包含松醇、d-手性肌醇或它们的类似化合物作为有效成分的用于改善、预防或治疗女性更年期症状的组合物 |
CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
WO2023048174A1 (ja) * | 2021-09-22 | 2023-03-30 | テイカ製薬株式会社 | 角膜疾患治療剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
ES2423899T3 (es) * | 2000-08-30 | 2013-09-25 | Unimed Pharmaceuticals, Llc | Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres |
US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
DE60139625D1 (de) * | 2001-12-07 | 2009-10-01 | Besins Int Belgique | Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
-
2006
- 2006-04-11 KR KR1020077026271A patent/KR20080016552A/ko not_active Application Discontinuation
- 2006-04-11 CA CA002604431A patent/CA2604431A1/en not_active Abandoned
- 2006-04-11 JP JP2008506606A patent/JP2008536851A/ja active Pending
- 2006-04-11 WO PCT/US2006/013550 patent/WO2006113242A2/en active Application Filing
- 2006-04-11 US US11/402,986 patent/US20070154533A1/en not_active Abandoned
- 2006-04-11 EP EP06740872A patent/EP1868590A4/en not_active Withdrawn
-
2007
- 2007-11-13 NO NO20075821A patent/NO20075821L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008536851A5 (ja) | 女性でテストステロンおよび関連ステロイドの濃度を増加させる医薬組成物および医薬キット | |
JP4293293B2 (ja) | エストローゲン、プロゲスチンあるいはそれら混合物の新規なる経皮投与用組成物 | |
CA2451725C (en) | Therapeutic combinations for the treatment of hormone deficiencies | |
Kuhl | Pharmacokinetics of oestrogens and progestogens | |
CA2419573C (en) | Method of increasing testosterone and related steroid concentrations in women | |
US20030022877A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
US20150250801A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
JP2009512658A5 (ja) | ||
AU2012210691B2 (en) | Testosterone formulations | |
JP2008538753A5 (ja) | 骨の老化または骨粗しょう症の治療または予防用組成物 | |
CA2533312A1 (en) | Transdermal hormone delivery system: compositions and methods | |
US20110306582A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
AU2001285367A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
JP2016505006A5 (ja) | ||
CA2519980A1 (en) | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen | |
ES2340925T3 (es) | Sistema de suministro transdermico de gestodeno. | |
CA2380769A1 (en) | Transdermal delivery of lasofoxifene | |
JP4965263B2 (ja) | 浸透増強剤を必要としないホルモンの経皮送達 | |
AU2003228314C1 (en) | Androgen pharmaceutical composition and method for treating depression | |
JP2000143513A (ja) | 外用組成物 | |
JP2002087964A (ja) | 性機能低下を治療するための医薬組成物及び方法 | |
RU2286787C2 (ru) | Способ повышения концентрации тестостерона и родственных стероидов у женщин | |
Prasad | International Journal of Nanomedicine and Nanosurgery | |
Messerlian et al. | Urinary phthalate metabolite concentrations were associated with pregnancy loss among women conceiving with medically assisted reproduction | |
CA2501846A1 (en) | Therapeutic combinations for the treatment of hormone deficiencies |